Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. (Registro nro. 16588)
[ vista simple ]
000 -CABECERA | |
---|---|
Campo de control de longitud fija | nab a22 7a 4500 |
003 - IDENTIFICADOR DEL NÚMERO DE CONTROL | |
Campo de control | PC16588 |
005 - FECHA Y HORA DE LA ÚLTIMA TRANSACCIÓN | |
Campo de control | 20211005130755.0 |
008 - CÓDIGOS DE INFORMACIÓN DE LONGITUD FIJA | |
Campo de control de longitud fija | 210825b xxu||||| |||| 00| 0 eng d |
040 ## - FUENTE DE LA CATALOGACIÓN | |
Centro transcriptor | H12O |
041 ## - CÓDIGO DE LENGUA | |
Código de lengua del texto/banda sonora o título independiente | eng |
100 ## - PUNTO DE ACCESO PRINCIPAL - NOMBRE DE PERSONA | |
9 (RLIN) | 390 |
Nombre de persona | Cedena Romero, María Teresa |
Término indicativo de función | Hematología |
245 00 - MENCIÓN DE TÍTULO | |
Título | Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. |
Tipo de material | [artículo] |
260 ## - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) | |
Nombre del editor distribuidor etc. | Leukemia & lymphoma, |
Fecha de publicación distribución etc. | 2014 |
300 ## - DESCRIPCIÓN FÍSICA | |
Extensión | 55(6):1300-3. |
500 ## - NOTA GENERAL | |
Nota general | Formato Vancouver: Xicoy B, Jiménez MJ, García O, Bargay J, Martínez Robles V, Brunet S et al. Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes. Leuk Lymphoma. 2014 Jun;55(6):1300-3. |
501 ## - NOTA DE “CON” | |
Nota de "Con" | PMID: 23952246 |
504 ## - NOTA DE BIBLIOGRAFÍA; ETC. | |
Nota de bibliografía etc. | Contiene 17 referencias |
520 ## - NOTA DE SUMARIO; ETC. | |
Sumario etc. | The tolerability of azacitidine (AZA) allows its administration in elderly patients. The objective of this study was to analyze the clinical and biological characteristics, transfusion independence (TI), overall survival (OS) and toxicity in a series of 107 patients ≥ 75 years of age from the Spanish Registry of Myelodysplastic Syndromes (MDS) treated with AZA. The median age (range) was 78 (75-90) years. According to the World Health Organization (WHO) classification, 86/102 (84%) had MDS, 10/102 (10%) had mixed myeloproferative/myelodysplastic disorder and 6/102 (6%) had acute myeloblastic leukemia. Regarding MDS by the International Prognostic Scoring System on initiation of AZA, 38/84 (45%) were low-intermediate-1 risk and 46/84 (55%) were intermediate-2-high risk. Ninety-five patients (89%) were red blood cell or platelet transfusion dependent. The AZA schedule was 5-0-0 in 39/106 (37%) patients, 5-2-2 in 36/106 (34%) patients and 7 consecutive days in 31/106 (29%) patients. The median number of cycles administered was 8 (range, 1-30). Thirty-eight out of 94 (40%) patients achieved TI. Median OS (95% confidence interval [CI]) was significantly better in patients achieving TI (n = 38) compared to patients who did not (n = 56) (22 [20.1-23.9] months vs. 11.1 [4.8-17.5] months, p = 0.001). No significant differences were observed in TI rate and OS among the three different schedules. With a median follow-up of 14 (min-max, 1-50) months, the median OS (95% CI) of the 107 patients was 18 (12-23) months and the probability of OS (95% CI) at 2 years was 34% (22-46%). Cycles were delayed in 31/106 (29%) patients and 47/101 patients (47%) were hospitalized for infection. These results show that treatment with AZA was feasible and effective in this elderly population, with 40% achieving TI, having a better OS than patients not achieving it. The schedule of AZA administration did not affect efficacy and toxicity. |
710 ## - PUNTO DE ACCESO ADICIONAL - NOMBRE DE ENTIDAD | |
9 (RLIN) | 297 |
Nombre de entidad o nombre de jurisdicción como elemento inicial | Servicio de Hematología y Hemoterapia |
856 ## - LOCALIZACIÓN Y ACCESO ELECTRÓNICOS | |
Identificador Uniforme del Recurso (URI) | http://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/1/pc16588.pdf |
Acceso | Solicitar documento |
942 ## - ENTRADA PARA ELEMENTOS AGREGADOS (KOHA) | |
Fuente de clasificación o esquema de ordenación en estanterías | |
Koha [por defecto] tipo de item | Artículo |
Suprimido en OPAC | Público |
Suprimido | Estado de pérdida | Fuente de clasificación o esquema de ordenación en estanterías | Estropeado | No para préstamo | Localización permanente | Localización actual | Fecha de adquisición | Signatura completa | Fecha última consulta | Fecha del precio de reemplazo | Tipo de item de Koha |
---|---|---|---|---|---|---|---|---|---|---|---|
Hospital Universitario 12 de Octubre | Hospital Universitario 12 de Octubre | 2021-08-25 | PC16588 | 2021-08-25 | 2021-08-25 | Artículo |